BRCA2 and colorectal carcinoma: Germline mutations in BRCA are currently on the rise as a risk factor for CRC due to the significantly increased risk of early-onset CRC in BRCA mutation carriers [99]; therefore, YU238259 may have significant clinical potential as a new radiosensitizing agent in BRCA2-negative CRC patients.